KR880012637A - Ⅱ-아릴에스트란 및 ⅱ-아릴프레그난 유도체 - Google Patents

Ⅱ-아릴에스트란 및 ⅱ-아릴프레그난 유도체 Download PDF

Info

Publication number
KR880012637A
KR880012637A KR1019880004653A KR880004653A KR880012637A KR 880012637 A KR880012637 A KR 880012637A KR 1019880004653 A KR1019880004653 A KR 1019880004653A KR 880004653 A KR880004653 A KR 880004653A KR 880012637 A KR880012637 A KR 880012637A
Authority
KR
South Korea
Prior art keywords
group
compound
hydroxyl
compound according
acyloxy
Prior art date
Application number
KR1019880004653A
Other languages
English (en)
Other versions
KR970005318B1 (ko
Inventor
베르나드 그로엔 마리누스
파울 데죤 헨드릭
Original Assignee
에이.쥐.제이.베르메렌·에.디.도우마
악조 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이.쥐.제이.베르메렌·에.디.도우마, 악조 엔.브이. filed Critical 에이.쥐.제이.베르메렌·에.디.도우마
Publication of KR880012637A publication Critical patent/KR880012637A/ko
Application granted granted Critical
Publication of KR970005318B1 publication Critical patent/KR970005318B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

11-아릴에스트란 및 11-아릴프레그난 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 하기 구조식을 가지는 것을 특징으로 하는 11-아릴에스트란 및 11-아릴프레그난유도체.
    식중, R1은 치환체 X 및 Y가 각각 H 또는 (1-4)C 탄화수소 라디칼이거나 (2-6)C 탄화수소라디칼인를 가진 아릴기이고, R2는 (1-4)C를 함유하는 알킬기이고, R3은 H, OH, (1-8)C를 함유하고 적어도 히드록실, 옥소, 할로겐, 아지도 또는 니트릴기를 포함하는 포화 또는 불포화탄화수소, 또는 아실옥시 또는 알콕시기이고, R4는 히드록실, 아실옥시 또는 알콕시기, 또는 히드록실, 알콕시, 아실옥시 또는 할로겐기로 임의 치환된 아실기이고, 또는 R3과 R4가 함께 고리를 형성하고, R5는 (1-4)C를 함유하는 탄화수소라디칼이다.
  2. 제 1항에 있어서, R1이 하기구조식을 가지는 아미노페닐기인것을 특징으로 하는 화합물.
    식중, X 및 Y는 각각 (1-4)C 함유알킬이다.
  3. 제 1항 또는 제 2항에 있어서, R2가 메틸인것을 특징으로 하는 화합물.
  4. 제 1항 내지 제 3항에 있어서, R3가 (1-4)C 및 1또는 2개의히드록실기를 함유하는 불포화 알킬기인 것을 특징으로하는 화합물.
  5. 제 1항 내지 제 3항에 있어서, R3및 R4가 함께 고리를 형성하는 것을 특징으로하는 화합물.
  6. 제 1항 내지 제 4항에 있어서, R4가 히드록실기인 것을 특징으로 하는 화합물.
  7. 제 1항 내지 제 6항에 있어서, R5가 (1-4)C 함유 알킬기인 것을 특징으로 하는 화합물.
  8. 하기구조식의 화합물을 탈수 및 가수분해하여 제조하는 것을 특징으로 하는 제 1항의 화합물의 제조방법.
    식중, R1, R2, R3, R4및 R5는 제 1항에서의 정의와 동일하고, R3및/또는 R4가 산소함유기인 경우에는 R3및/또는 R4는 산소원자가 가수분해성기에 의해 보호된 산소 함유기일수도 있고, R6및 R7은 (1-4)C 함유 알킬기이거나 R6과 R7이 함께 (2-5)C 함유 알킬렌기를 형성한다.
  9. 적어도 하나의 제 1항의 화합물을 포함하는 약학조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880004653A 1987-04-24 1988-04-23 11-아릴에스트란 및 11-아릴프레그난 유도체 KR970005318B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL8700970 1987-04-24
NL8700970 1987-04-24
NL87.00970 1987-04-24

Publications (2)

Publication Number Publication Date
KR880012637A true KR880012637A (ko) 1988-11-28
KR970005318B1 KR970005318B1 (ko) 1997-04-15

Family

ID=19849909

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880004653A KR970005318B1 (ko) 1987-04-24 1988-04-23 11-아릴에스트란 및 11-아릴프레그난 유도체

Country Status (17)

Country Link
US (1) US4871724A (ko)
EP (1) EP0289073B1 (ko)
JP (1) JP2655676B2 (ko)
KR (1) KR970005318B1 (ko)
CN (1) CN1019978C (ko)
AT (1) ATE69820T1 (ko)
AU (1) AU608831B2 (ko)
CA (1) CA1297472C (ko)
DE (1) DE3866410D1 (ko)
DK (1) DK168294B1 (ko)
ES (1) ES2045082T3 (ko)
FI (1) FI88396C (ko)
GR (1) GR3003363T3 (ko)
IE (1) IE60783B1 (ko)
NZ (1) NZ224355A (ko)
PT (1) PT87322B (ko)
ZA (1) ZA882643B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010853D1 (de) * 1989-08-04 1998-12-03 Schering Ag 11 Beta-Aryl-gona-4,9-dien-3-one
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
ZA929315B (en) * 1991-12-20 1993-05-24 Akzo Nv 17-spirofuran-3'-ylidene steroids.
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4434488A1 (de) 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
ZA9510926B (en) 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
CN1117759C (zh) * 1999-09-02 2003-08-13 上海中西药业股份有限公司 甾体化合物,其制备方法和其药物组合物及其应用
TW200531977A (en) 2004-03-25 2005-10-01 Akzo Nobel Nv Progesterone receptor modulators
EP3693376A1 (en) 2006-10-24 2020-08-12 Allergan Pharmaceuticals International Limited Compositions for suppressing endometrial proliferation
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
WO2011119194A1 (en) 2010-03-22 2011-09-29 Repros Therapeutics Inc. Compositions and methods for non-toxic delivery of antiprogestins
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424769A (en) * 1966-04-04 1969-01-28 Syntex Corp Process for the preparation of novel 6alpha-methyl-delta4,9(10)- diene steroids
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
EP0116974B1 (de) * 1983-02-18 1986-10-29 Schering Aktiengesellschaft 11-Beta-Aryl-Estradiene, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
AU580843B2 (en) * 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
US4678282A (en) * 1985-02-19 1987-07-07 Ovonic Imaging Systems, Inc. Active display matrix addressable without crossed lines on any one substrate and method of using the same
GB8513723D0 (en) * 1985-05-31 1985-07-03 Erba Farmitalia 11-beta substituted steroids

Also Published As

Publication number Publication date
KR970005318B1 (ko) 1997-04-15
EP0289073A1 (en) 1988-11-02
GR3003363T3 (en) 1993-02-17
NZ224355A (en) 1990-03-27
FI881826A0 (fi) 1988-04-19
PT87322B (pt) 1992-08-31
ES2045082T3 (es) 1994-01-16
FI88396C (fi) 1993-05-10
ZA882643B (en) 1988-10-04
JP2655676B2 (ja) 1997-09-24
AU1507288A (en) 1988-10-27
IE60783B1 (en) 1994-08-10
DE3866410D1 (de) 1992-01-09
DK221888A (da) 1988-10-25
EP0289073B1 (en) 1991-11-27
PT87322A (pt) 1988-05-01
AU608831B2 (en) 1991-04-18
ATE69820T1 (de) 1991-12-15
IE881131L (en) 1988-10-24
CA1297472C (en) 1992-03-17
DK221888D0 (da) 1988-04-22
FI881826A (fi) 1988-10-25
CN1019978C (zh) 1993-03-03
US4871724A (en) 1989-10-03
CN88102416A (zh) 1988-12-14
DK168294B1 (da) 1994-03-07
JPS63280097A (ja) 1988-11-17
FI88396B (fi) 1993-01-29

Similar Documents

Publication Publication Date Title
KR880012637A (ko) Ⅱ-아릴에스트란 및 ⅱ-아릴프레그난 유도체
GB1441424A (en) Surface-active compositions
KR850000406A (ko) 4-클로로-2-페닐이미다졸-5-아세트산유도체의 제조방법
KR870006039A (ko) 신규 티아졸 화합물, 그 제조방법 및 이 화합물을 함유하는 약학적 조성물
KR840008651A (ko) 퓨로-(3,4-c)-피리딘 유도체의 제조방법
KR890008086A (ko) 사이클로헥산 유도체
UST984005I4 (en) Yellow-dye-forming couplers
KR950032238A (ko) 유기물질용 안정화제로서 유용한, 실란기를 함유하는 1-히드로카르빌옥시-피페리딘 화합물 및 이를 함유하는 조성물
KR830007549A (ko) 2-옥소아제티딘 유도체의 제법
KR830006198A (ko) 시클로헥산 유도체의 제조방법
KR870007894A (ko) 신규이미다졸 화합물의 제조방법
KR910009837A (ko) 탄성중합체용 안정화제 혼합물
KR890014783A (ko) 금속표면 처리방법
KR840008342A (ko) 모르포린 유도체의 제조방법
KR830006403A (ko) 광학적 광택제 혼합물
KR830005641A (ko) 살균성을 갖는 중합체
KR850003407A (ko) 유기인산 에스테르 유도체의 제조방법
KR850003658A (ko) N-글리코실화 카르복스아미드 유도체-함유성장-촉진제
KR880005095A (ko) 2,4-디아미노-3-옥시-피리미딘 유도체의 제조방법
KR850000034A (ko) 테트라하이드로-β-카르보린 유도체의 제조방법
KR830007545A (ko) 프로스타글란딘의 제조방법
KR840009102A (ko) 치환된 이소퀴놀린 유도체의 제조방법
KR830004209A (ko) 옥타데센산 아미드의 제법
KR830009135A (ko) 4-피라졸릴 아린산 에스테르 유도체 및 그 제조방법
KR940005807A (ko) 가죽과 모피의 타닝 방법

Legal Events

Date Code Title Description
AMND Amendment
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E801 Decision on dismissal of amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20000407

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee